HD-OPM Archive
Topics › Statins

PD-STAT: simvastatin did not slow Parkinson's progression in a 235-person randomized trial

Louis Nervegna · Mar 23, 2026 · ♥ 5 reactions · 0 comments · original Facebook post
StatinsBrain health & dementia
AI summary & key facts

Louis explains that the 2-year PD-STAT trial found simvastatin neither slowed nor accelerated Parkinson's disease progression versus placebo in 235 people with moderate disease at hospitals in England. Simvastatin was chosen partly because lipophilic statins cross the blood-brain barrier more easily.

Statins do not slow progression of Parkinson’s Disease.

(Nor do they accelerate progression.)

These were the results of the PD-STAT randomized controlled trial.

This 2-year trial tested simvastatin as a treatment for moderate-stage Parkinson’s Disease, in a total of 235 people at 35 different hospital sites in England.

(Note that simvastatin is highly lipophilic. That’s a major reason why it was chosen for this trial. This makes it much easier to cross the blood barrier than hydrophilic statins like rosuvastatin.)

Quoted:

Initial results from the PD-STAT trial show that, in comparison with a placebo (dummy drug), simvastatin was ‘futile’ in slowing the rate of progression of Parkinson’s.

PD-STAT examined whether simvastatin, a widely-used cholesterol-lowering drug, had the potential to reduce the rate of neurodegenerative decline in people with Parkinson’s.

The 2 year trial funded by The Cure Parkinson’s Trust was conducted at 23 hospitals across England, with 235 participants with moderate stage Parkinson’s. Participants were randomly assigned to receive either simvastatin or a placebo for 2 years, followed by a final study assessment of their Parkinson’s 2 months later.

Previous research showed that statin use may lower the risk of developing Parkinson’s. Lab studies suggested statin drugs may protect brain cells from damaging processes involved in Parkinson’s. Simvastatin has also shown promise for slowing the progression of multiple sclerosis.

Claire Bale, Head of Research Communications & Engagement at Parkinson's UK, said:

"These results are disappointing but mean we can now move on to focus on other promising opportunities to find new and better treatments for Parkinson’s.

#statinsHD #parkinsonsHD #statinsparkinsonsHD

Parkinson's UKTrial results show statin drug does not slow Parkinson'sSimvastatin is a drug already used to lower cholesterol, and prevent heart attacks and strokes. Initial results from a major clinical trial show it doesn't have potential to slow the progression of Parkinson's as previously hoped.parkinsons.org.uk

Research cited

← newer: ASPC releases an upside-down food pyramid based on global caolder: YELLOW-III reversed total atheroma volume 4.4% in 6 months a →